| Market Cap | 114.99M | P/E | - | EPS this Y | -4.90% | Ern Qtrly Grth | - |
| Income | -117.67M | Forward P/E | -0.87 | EPS next Y | 39.20% | 50D Avg Chg | 2.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -1.00% |
| Dividend | N/A | Price/Book | 0.54 | EPS next 5Y | - | 52W High Chg | -31.00% |
| Recommedations | 2.30 | Quick Ratio | 5.17 | Shares Outstanding | 38.33M | 52W Low Chg | 36.00% |
| Insider Own | 2.19% | ROA | -37.97% | Shares Float | 26.94M | Beta | 2.78 |
| Inst Own | 62.85% | ROE | -64.42% | Shares Shorted/Prior | 1.01M/783.58K | Price | 3.03 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 257,546 | Target Price | 7.42 |
| Oper. Margin | - | Earnings Date | May 9 | Volume | 251,117 | Change | 4.48% |
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
| JMP Securities | Outperform | Aug 11, 23 |
| Mizuho | Buy | May 15, 23 |
| BTIG | Buy | Mar 30, 23 |
| JMP Securities | Market Outperform | Mar 24, 23 |
| Mizuho | Buy | Jul 7, 22 |
| Stifel | Hold | Jun 23, 22 |
| JMP Securities | Market Perform | Jun 23, 22 |
| Jefferies | Hold | Jun 23, 22 |
| BTIG | Buy | May 10, 22 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Gengos Andrew | See Below See Below | Jan 04 | Sell | 2.91 | 1,208 | 3,515 | 83,804 | 01/08/24 |
| PERCEPTIVE ADVISORS LLC | Director Director | Dec 27 | Buy | 2.37 | 605,686 | 1,435,476 | 5,402,964 | 12/29/23 |
| Gengos Andrew | See Below See Below | Jun 07 | Buy | 3.4 | 15,000 | 51,000 | 80,012 | 06/09/23 |
| Gengos Andrew | See Below See Below | Jun 02 | Buy | 2.94 | 65,012 | 191,135 | 65,012 | 06/06/23 |
| MOEBIUS HANS | Chief Medical Office.. Chief Medical Officer | Jun 02 | Option | 1.35 | 7,882 | 10,641 | 81,482 | 06/06/23 |
| PICKERING GRANT | Director Director | Mar 29 | Buy | 2.4 | 25,000 | 60,000 | 25,783 | 03/31/23 |
| JOHNSON JAMES A | Director Director | Mar 29 | Buy | 2.40 | 5,000 | 12,000 | 5,000 | 03/30/23 |
| MILESON GLENNA | Chief Financial Offi.. Chief Financial Officer | Dec 28 | Buy | 2.85 | 50,000 | 142,500 | 159,930 | 12/30/22 |
| Romano Kelly A | Director Director | Dec 02 | Buy | 3.29 | 30,000 | 98,700 | 38,315 | 12/06/22 |
| CHURCH KEVIN | Executive VP, Resear.. Executive VP, Research | Oct 28 | Option | 1.35 | 3,700 | 4,995 | 61,395 | 10/31/22 |
| MOEBIUS HANS | Chief Medical Office.. Chief Medical Officer | Oct 13 | Option | 1.35 | 7,881 | 10,639 | 60,836 | 10/17/22 |
| PERCEPTIVE ADVISORS LLC | Director Director | Jun 29 | Buy | 2.99 | 1,371,362 | 4,100,372 | 4,797,278 | 07/01/22 |
| MOEBIUS HANS | Chief Medical Office.. Chief Medical Officer | Jun 28 | Buy | 2.88 | 10,000 | 28,800 | 52,955 | 06/30/22 |
| Worthington Mark | General Counsel General Counsel | Jun 22 | Sell | 2.69 | 2,614 | 7,032 | 19,097 | 06/24/22 |
| MILESON GLENNA | Chief Financial Offi.. Chief Financial Officer | Jun 22 | Sell | 2.69 | 2,614 | 7,032 | 109,167 | 06/24/22 |
| Litton Mark James | Chief Executive Offi.. Chief Executive Officer | Jun 22 | Sell | 2.69 | 7,960 | 21,412 | 128,555 | 06/24/22 |
| Lenington Rachel | Chief Operating Offi.. Chief Operating Officer | Jun 22 | Sell | 2.69 | 4,193 | 11,279 | 5,807 | 06/24/22 |
| CHURCH KEVIN | Executive VP, Resear.. Executive VP, Research | Jun 22 | Sell | 2.69 | 2,614 | 7,032 | 57,695 | 06/24/22 |
| CHURCH KEVIN | Executive VP, Resear.. Executive VP, Research | Jun 08 | Option | 1.35 | 2,500 | 3,375 | 50,309 | 06/10/22 |
| MILESON GLENNA | Chief Financial Offi.. Chief Financial Officer | Apr 12 | Option | 10.64 | 3,000 | 31,920 | 100,060 | 04/12/22 |
| CHURCH KEVIN | Executive VP, Resear.. Executive VP, Research | Feb 18 | Option | 1.19 | 3,152 | 3,751 | 47,566 | 02/18/22 |